Regenxbio Inc at RBC Capital Markets Global Healthcare Conference Transcript
(audio in progress) around regulatory and why waiting? You guys have been pretty clear that you'd like to wait to submit that data set until the new leadership team at the FDA is in place. There's maybe a counterargument to be made that control the controllable. That's something you can control. Just maybe walk us through what are the primary advantages of actually waiting to submit this data set?
Questions & Answers
Yeah, I actually would probably want to clarify. The waiting aspect of that is further discussions with FDA. What we're looking to do is see FDA stabilize in terms of new leadership, additional changes last week, as everybody saw. I think we look at all the changes as really, really positive in the sense of particularly in rare disease, where the patient advocacy groups and patients are in great need for alternative therapies to come to market. As it relates to the Duchenne data, we think the top-line data checks every box that you need for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
